HOME >> BIOLOGY >> NEWS
New tuberculosis antibiotic may shorten treatment time, fight drug-resistant strains

This release is also available in French.

A new antibiotic shows promise, thus far in mice, for treating tuberculosis much faster than current drugs do, scientists report. Additional evidence indicates that the antibiotic may work against multidrug-resistant strains of the tuberculosis bug. Studies in healthy human volunteers have indicated that the drug is safe for humans to take, and further human studies are currently underway.

These findings, by Koen Andries of Johnson & Johnson Pharmaceutical Research and Development, LLC in Beerse, Belgium and colleagues, will appear online in the 9 December Science Express, part of the journal Science, published by AAAS, the nonprofit science society.

Globally, tuberculosis is second only to AIDS as a leading cause of death from infectious disease, causing approximately two million deaths per year. The tuberculosis and HIV epidemics fuel one another; at least 11 million adults are infected with both pathogens, according to the Global Alliance for TB Drug Development.

No new tuberculosis-specific drugs have been discovered in the last 40 years, and emerging strains of the bacterium that are resistant to multiple drugs are an increasingly worrisome problem. The current treatment for drug-sensitive tuberculosis recommended by the World Health Organization consists of a cocktail of drugs that must be taken for six to nine months.

"The world desperately needs a new tuberculosis drug that can combat resistant strains of the bacterium and that is easier for patients to take. The evidence thus far suggests that this new drug lead may be up to both tasks, which is encouraging news for global health," said Katrina Kelner, Deputy Editor, life sciences, at Science.

"If this drug is ultimately approved for humans, it could lead to a change in treatment paradigm for tuberculosis," Andries said.

The dr
'"/>

Contact: Jessica Lawrence-Hurt
jlawrenc@aaas.org
1-202-326-7088
American Association for the Advancement of Science
9-Dec-2004


Page: 1 2 3 4

Related biology news :

1. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
2. Handicapping tuberculosis may be the way to a better vaccine
3. Developing a more effective vaccine for tuberculosis
4. Why is long-term therapy required to cure tuberculosis?
5. UA researchers identify new adherence factor, Pili, produced by tuberculosis
6. Shorter tuberculosis therapies could lead to substantial reductions in cases and deaths
7. Pitt phage hunter takes on tuberculosis
8. Cost-effectiveness of treating multidrug-resistant tuberculosis
9. New potential drug target in tuberculosis
10. National Institutes of Health funds $13.7 million for Texas tuberculosis study
11. Einstein researchers find potential new drugs for tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/23/2018)... ... November 23, 2018 , ... uBiome, the leader in ... the G. Oppenheimer Center for Neurobiology of Stress and Resilience, to its Medical ... world, Dr. Mayer will bring to uBiome his expertise on the connections between ...
(Date:11/20/2018)... ... November 19, 2018 , ... ... tools, drug development, agriculture, human clinical therapeutics, and animal and disease model), by ... (drug compound and target screening, and agriculture and industrial use), by Patent Activities ...
(Date:11/20/2018)... ... November 20, 2018 , ... Thanks to its long-standing expertise in ID ... ID reader market, as the company now proposes a full range of readers able ... ID reader range can be used by professionals either in a fixed location or ...
Breaking Biology News(10 mins):
(Date:12/5/2018)... ... ... The incredible life story of former refugee and LG Sonic CEO Yousef ... the European Commissioner for Research and Innovation. , In his November 27th speech ... spoke at length of Yousef’s life and journey, citing the man who convinced him ...
(Date:11/29/2018)... LEHI, Utah (PRWEB) , ... November 29, 2018 , ... ... round was led by Kickstart Seed Fund, with participation from existing investor and board ... Investors and Davis Smith of Cotopaxi. The additional funding will enable the company to ...
(Date:11/26/2018)... ... November 26, 2018 , ... USARAD Holdings Inc., the ... Venture Partners (Virtual Radiologic founders) among other healthcare investors exhibits at the Radiological ... Place in Chicago. The company is proud to announce a 10 year anniversary ...
(Date:11/20/2018)... ... November 20, 2018 , ... Each year Forbes receives thousands ... list which highlights outstanding performance by individuals under 30 years of age. The Forbes ... fields from Sports and Entertainment to Venture Capital and Science. , In 2017, ...
Breaking Biology Technology:
Cached News: